Scarica l'app Stockscreener
2.63
1.15%
0.03
Dopo l'orario di chiusura:
2.66
0.03
+1.14%
Precedente Chiudi:
$2.60
Aprire:
$2.61
Volume 24 ore:
832.91K
Relative Volume:
0.98
Capitalizzazione di mercato:
$241.64M
Reddito:
-
Utile/perdita netta:
$-36.12M
Rapporto P/E:
-6.8418
EPS:
-0.3844
Flusso di cassa netto:
$-28.42M
1 W Prestazione:
+21.20%
1M Prestazione:
+16.37%
6M Prestazione:
+132.74%
1 anno Prestazione:
+279.56%
Intervallo 1D:
$2.525
$2.65
Intervallo di 1 settimana:
$2.15
$2.65
Portata 52W:
$0.49
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Nome
Context Therapeutics Inc
Settore
Industria
Telefono
267-225-7416
Indirizzo
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
2.63 | 238.89M | 0 | -36.12M | -28.42M | -0.3844 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-11-25 | Iniziato | D. Boral Capital | Buy |
| 2024-05-16 | Iniziato | Piper Sandler | Overweight |
Context Therapeutics Inc Borsa (CNTX) Ultime notizie
Context Therapeutics (CNTX) Surges Over 8% Amid Renewed Buying Interest Above Key SupportSign of Weakness - Newser
CNTX Q1 2026 Earnings: Context Therapeutics Beats EPS Estimates with Narrower-Than-Expected LossGuidance Revision Trend - Newser
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
CNTX News | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Context Therapeutics Decline Means Insider Profits Down To US$237k - simplywall.st
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
Why Is Context Therapeutics Inc. (CNTX) Stock Down Today? - Meyka
Why Is Context Therapeutics Inc. (CNTX) Stock Up Today? - Meyka
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal - Moomoo
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Context Therapeutics Secures Full Rights to Antibody Assets - TipRanks
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free - TradingView
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 - marketscreener.com
Context Therapeutics Inc. Announces Amendment to License Agreement for CT-202, Securing Full Economic Rights - Quiver Quantitative
Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license - Stock Titan
Context Therapeutics Enters into License Agreement Amendment with BioAtla - marketscreener.com
Context Therapeutics Advances Cancer Drug Pipeline Toward Data Readouts - MyChesCo
Context Therapeutics (CNTX) Slips -6.87%, Testing $2.06 Support 2026-05-15Fast Rising Picks - Newser
Context Therapeutics (CNTX) Crushes Q1 2026 Estimates — EPS $-0.09 Tops ViewsSocial Buy Zones - Newser
Context Therapeutics (CNTX) joint filing shows 2.44% ownership by Great Point Partners - Stock Titan
Blue Owl Capital Holdings (CNTX) Discloses 5.54% Ownership in Context Therapeutics - Stock Titan
Octagon, Master Fund, Ting Jia file 5.25M-share holding in CNTX (5.7%) - Stock Titan
Avidity entities hold 8.7% of Context Therapeutics (NASDAQ: CNTX) - Stock Titan
Lifesci Capital Issues Positive Estimate for CNTX Earnings - MarketBeat
HC Wainwright Issues Optimistic Outlook for CNTX Earnings - MarketBeat
LifeSci Capital Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Soleus entities (CNTX) report 6.96M shares, 7.6% stake disclosed - Stock Titan
A Quick Look at Today's Ratings for Context Therapeutics(CNTX.US), With a Forecast Between $5 to $7 - Moomoo
Piper Sandler Sticks to Its Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
CNTX Context Therapeutics Q4 loss widens, misses estimates by 29%; shares drop 3.3% on earnings disappointment.Outlook Update - Newser
What makes Context Therapeutics (CNTX) a compelling holding for the long term (-3.32%) 2026-05-08Bearish Pattern Stocks - Newser
Context Therapeutics Inc. (CNTX) Eps Diluted (TTM) - Zacks Investment Research
Cancer drug developer maps 3 trial milestones as cash lasts to 2027 - Stock Titan
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results - GlobeNewswire
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Context Therapeutics (NASDAQ: CNTX) widens Q1 2026 loss as R&D climbs - Stock Titan
CNTX Earnings History & Surprises | EPS & Revenue Results | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Context Therapeutics settles governance lawsuit with mootness fee - TipRanks
Context Therapeutics (NASDAQ: CNTX) ends charter suit with $850K mootness fee - Stock Titan
H.C. Wainwright Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Context Therapeutics (CNTX) to Release Quarterly Earnings on Wednesday - MarketBeat
[ARS] Context Therapeutics Inc. SEC Filing - Stock Titan
Context Therapeutics (NASDAQ: CNTX) plans vote on board slate and 300M-share authorization - Stock Titan
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock - Yahoo Finance
Context Therapeutics (CNTX) price target increased by 13.33% to 5.78 - MSN
Is Context Therapeutics (CNTX) stock a good candidate for diversification | Q4 2025: EPS Misses EstimatesMarket Risk - Xã Thanh Hà
CNTX (Context Therapeutics Inc.) shares rise 6.11 percent even as Q4 2025 EPS lands below consensus analyst estimates.Trending Volume Leaders - Xã Thanh Hà
Is Context Therapeutics (CNTX) stock forming lower lows | Q4 2025: EPS Misses EstimatesPayout Ratio - Xã Vĩnh Công
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Piper Sandler Reaffirms Their Buy Rating on Context Therapeutics (CNTX) - The Globe and Mail
Context Therapeutics Inc Azioni (CNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Context Therapeutics Inc Azioni (CNTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):